GlassScriptPhysician profile
Cheryl Mckee
NPI 1346870136
$8,096.37
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,545 · 2022: $3,195 · 2023: $2,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,356.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,706.45 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $616.13 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $598.78 | 2021-2023 | Austedo |
| Lundbeck LLC | $510.50 | 2021-2023 | Vyepti |
| Supernus Pharmaceuticals, INC. | $491.07 | 2021-2022 | |
| Mdd US Operations, LLC | $456.68 | 2022-2023 | Gocovri |
| Lilly USA, LLC | $450.37 | 2021-2023 | Emgality, Reyvow, Amyvid |
| Biohaven Pharmaceutical Holding Company LTD. | $419.59 | 2022 | |
| Amneal Pharmaceuticals LLC | $389.92 | 2021-2023 | Rytary, Lyvispah |
| Sk Life Science, INC. | $308.05 | 2021-2023 | |
| Impel Pharmaceuticals INC. | $203.47 | 2022-2023 | Trudhesa |
| Pfizer INC. | $184.13 | 2023 | |
| Biogen, INC. | $178.04 | 2021-2022 | |
| Amgen INC. | $171.36 | 2021-2023 | Aimovig |
| Neurocrine Biosciences, INC. | $135.52 | 2021-2023 | Ongentys, Ingrezza |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Mckee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.